Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

• Published in: The New England journal of medicine Vol. 381; no. 2; pp. 142 - 149
• Main Authors: Lipton, Richard B, Croop, Robert, Stock, Elyse G, Stock, David A, Morris, Beth A, Frost, Marianne, Dubowchik, Gene M, Conway, Charles M, Coric, Vladimir, Goadsby, Peter J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 11.07.2019
• Subjects: Administration, Oral; Adult; Analgesics - adverse effects; Analgesics - therapeutic use; Calcitonin; Calcitonin Gene-Related Peptide Receptor Antagonists - adverse effects; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; Cardiovascular disease; Diaries; Double-Blind Method; Drug dosages; Female; Headache; Humans; Male; Middle Aged; Migraine; Migraine Disorders - complications; Migraine Disorders - drug therapy; Nausea; Nausea - chemically induced; Oral administration; Pain; Patients; Peptides; Pharmaceuticals; Piperidines - adverse effects; Piperidines - therapeutic use; Placebos - therapeutic use; Pyridines - adverse effects; Pyridines - therapeutic use; Substance abuse treatment; Urinary tract
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1811090

Treatment with the oral calcitonin gene–related peptide receptor antagonist rimegepant resulted in freedom from migraine pain 2 hours after the dose in 20% of patients; 12% of the patients who received placebo were pain-free. Freedom from the most bothersome migraine symptom aside from pain 2 hours after the dose was reported in 38% of patients who received rimegepant and 25% who received placebo.